Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSTA36)

• Drug Name: Intedanib Drug Info
• Synonyms: Nintedanib; Vargatef; 656247-17-5; BIBF-1120; BIBF 1120; 928326-83-4; BIBF1120; Nintedanib (BIBF 1120); OFEV; UNII-G6HRD2P839; (Z)-methyl 3-((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenylamino)(phenyl)methylene)-2-oxoindoline-6-carboxylate; G6HRD2P839; CHEBI:85164; 1160294-26-7; Methyl (3z)-3-{[(4-{methyl[(4-Methylpiperazin-1-Yl)acetyl]amino}phenyl)amino](Phenyl)methylidene}-2-Oxo-2,3-Dihydro-1h-Indole-6-Carboxylate

Indication

Disease Entry	ICD 11	Status	REF
Colorectal cancer	2B91.Z	Approved	[1]
Idiopathic pulmonary fibrosis	CB03.4	Approved	[2]
Mesothelioma	2C51.2	Phase 3	[3]
Non-small-cell lung cancer	2C25.Y	Phase 3	[4]
Ovarian cancer	2C73	Phase 2	[4]

• Cross-matching ID:
  PubChem CID: 135423438
  ChEBI ID: CHEBI:85164
  CAS Number: CAS 656247-17-5
  TTD Drug ID: DMSTA36
  VARIDT Drug ID: DR00137

Molecule-Related Drug Atlas

Drug(s) Targeting Vascular endothelial growth factor receptor (VEGFR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fruquintinib	DMHOSCQ	Colorectal cancer	2B91.Z	Approved	[3]
Sulfatinib	DMPOTM4	Neuroendocrine cancer	2B72.1	Phase 3	[3]
KH-902	DM8VO16	Diabetic macular edema	9B71.02	Phase 3	[6]
ABP 938	DM00ACQ	Neovascular age-related macular degeneration	9B78.3Z	Phase 3	[7]
XL-820	DMMHX9K	Solid tumour/cancer	2A00-2F9Z	Phase 2	[8]
BAY-57-9352	DMVA5NS	Gastric adenocarcinoma	2B72	Phase 2	[9]
X-82	DMW1NKO	Age-related macular degeneration	9B75.0	Phase 2	[3]
Vorolanib	DMIM1U9	Non-small-cell lung cancer	2C25	Phase 2	[10]
BFH-772	DMVUX1C	Psoriasis vulgaris	EA90	Phase 2	[11]
ASP-8477	DMBZQS7	Neuropathic pain	8E43.0	Phase 2	[12]

Drug(s) Targeting Fibroblast growth factor receptor 1 (FGFR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[13]
Pemigatinib	DM819JF	Cholangiocarcinoma	2C12.10	Approved	[14]
Infigratinib	DMNKBEC	Cholangiocarcinoma	2C12.10	Approved	[15]
E-3810	DM42PFT	Solid tumour/cancer	2A00-2F9Z	Phase 3	[16]
Sulfatinib	DMPOTM4	Neuroendocrine cancer	2B72.1	Phase 3	[17]
ARQ-087	DM02BVQ	Intrahepatic cholangiocarcinoma	2C12.10	Phase 3	[18]
AZD4547	DM3827C	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[19]
Debio 1347	DMZW50O	Solid tumour/cancer	2A00-2F9Z	Phase 2	[3]
AM-001	DMGVQI8	Actinic keratosis	EK90.0	Phase 2	[20]
FGF-1	DMXMC8I	Coronary heart disease	BA80.Z	Phase 2	[21]

Drug(s) Targeting Platelet-derived growth factor receptor (PDGFR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[22]
Pazopanib HCl	DM6U9CQ	Renal cell carcinoma	2C90	Approved	[23]
CT-102	DMB8PF3	Diabetic foot ulcer	BD54	Approved	[24]
Trapidil	DMY67U8	Acute coronary syndrome	BA41	Phase 4	[25]
TKI258	DMYLT67	Renal cell carcinoma	2C90	Phase 3	[22]
BAY-57-9352	DMVA5NS	Gastric adenocarcinoma	2B72	Phase 2	[22]
X-82	DMW1NKO	Age-related macular degeneration	9B75.0	Phase 2	[26]
Vorolanib	DMIM1U9	Non-small-cell lung cancer	2C25	Phase 2	[10]
PMID25623274-Compound-WO2014132220C2	DMXEZWP	Pulmonary arterial hypertension	BB01.0	Patented	[27]
PMID25623274-Compound-WO2014132220C1	DMA2IMQ	Pulmonary arterial hypertension	BB01.0	Patented	[27]

Drug(s) Targeting Fms-like tyrosine kinase 3 (FLT-3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[28]
Ponatinib	DMYGJQO	Acute lymphoblastic leukaemia	2A85	Approved	[29]
Midostaurin	DMI6E0R	Acute myeloid leukaemia	2A60	Approved	[22]
Gilteritinib	DMTI0ZO	Acute myeloid leukaemia	2A60	Approved	[30]
Pexidartinib	DMS2J0Z	Tenosynovial giant cell tumour	2F7B	Approved	[31]
Pacritinib	DM1T6ZN	Myelofibrosis	2A20.2	Approved	[28]
Quizartinib	DM8Y4JS	Acute myeloid leukaemia	2A60	Approved	[3]
Lestaurtinib	DMQ2AIJ	Acute myeloid leukaemia	2A60	Approved (orphan drug)	[32]
Famitinib	DMSFWT7	Solid tumour/cancer	2A00-2F9Z	Phase 2	[33]
BMS-690514	DMX302C	Chronic pain	MG30	Phase 2	[34]

Drug(s) Transported By P-glycoprotein 1 (ABCB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[35]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[36]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[37]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[38]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[37]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[37]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[39]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[37]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[40]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[41]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Fibroblast growth factor receptor 1 (FGFR1)	TTRLW2X	FGFR1_HUMAN	Modulator	[1]
Fms-like tyrosine kinase 3 (FLT-3)	TTGJCWZ	FLT3_HUMAN	Inhibitor	[1]
Platelet-derived growth factor receptor (PDGFR)	TTI2WET	NOUNIPROTAC	Modulator	[1]
Vascular endothelial growth factor receptor (VEGFR)	TTVJ1D8	NOUNIPROTAC	Modulator	[1]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[5]

References

• [1] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5936).
• [5] Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Nintedanib in Healthy Subjects. Eur J Drug Metab Pharmacokinet. 2018 Oct;43(5):533-541.
• [6] Effects of intravitreal injection of KH902, a vascular endothelial growth factor receptor decoy, on the retinas of streptozotocin-induced diabetic rats. Diabetes Obes Metab. 2012 Jul;14(7):644-53.
• [7] Clinical pipeline report, company report or official report of Amgen
• [8] National Cancer Institute Drug Dictionary (drug id 452042).
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial. Chin J Cancer Res. 2021 Feb 28;33(1):103-114.
• [11] CA patent application no. 841416, Method of selecting therapeutic indications.
• [12] ClinicalTrials.gov (NCT02065349) A Study Into Pain Relief Given by ASP8477 for Peripheral Neuropathic Pain (Either Post-herpetic Neuralgia or Painful Diabetic Peripheral Neuropathy) and Its Safety. U.S. National Institutes of Health.
• [13] Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93.
• [14] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [15] Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets. J Bone Miner Res. 2013 Apr;28(4):899-911.
• [16] E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405.
• [17] Clinical pipeline report, company report or official report of Hutchison Medi Pharma.
• [18] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1808).
• [19] AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 2012 Apr 15;72(8):2045-56.
• [20] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029917)
• [21] Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer. 2002 Jun 17;86(12):1864-70.
• [22] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [23] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [24] Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
• [25] Osteitis fibrosa is mediated by Platelet-Derived Growth Factor-A via a phosphoinositide 3-kinase-dependent signaling pathway in a rat model for chr... Endocrinology. 2008 Nov;149(11):5735-46.
• [26] National Cancer Institute Drug Dictionary (drug id 695817).
• [27] Evaluation of WO-2014132220, selective PDGFR inhibitors for the treatment of pulmonary arterial hypertension.Expert Opin Ther Pat. 2015 Apr;25(4):493-9.
• [28] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1807).
• [29] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [30] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [31] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [32] Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with ... Blood. 2008 Jun 15;111(12):5663-71.
• [33] Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
• [34] Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. J Pharm Sci. 2010 Aug;99(8):3579-93.
• [35] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [36] MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
• [37] Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
• [38] Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
• [39] Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
• [40] Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
• [41] Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.